Mon. 15 Apr 2024, 7:15am ET
Benzinga
Biotech, News, Health Care, General
- Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine platform.
- Discovery of a novel immunodominance hierarchy of tumor neoantigens (including KRAS) enabled the development of a more potent, KRAS-specific vaccine candidate (SLATE-KRAS) being studied by Steven A. Rosenberg of the National Cancer Institute (NCI).
- Publication underscores the important role of antigen selection and cassette design in the development of neoantigen-directed immunotherapy.